#

IPO

: 299
US rejects Irans response to settle 10-week war: Donald Trump called it totally unacceptable / Photo: Studio Romantic / Shutterstock
Review·
Top stories for the morning: US rejects Iran's peace terms, Cerebras raises IPO valuation
Founded in 2021, Odyssey is developing therapies to treat patients with autoimmune diseases like ulcerative colitis, Crohn’s disease, and lupus / Photo: Odyssey Therapeutics
Small Caps·
Odyssey IPO: Immune system biotech debuts on the Nasdaq
Mobia Medicals development - Vivistim device for vagus nerve stimulation / Photo: Vivistim.com
News·
Mobia Medical IPO: developer of stroke rehabilitation systems goes public
BofA saw a threat to the market in the IPOs of SpaceX and Anthropic / Photo: FellowNeko / Shutterstock.com
News·
The huge IPOs of SpaceX and Anthropic could be the end of the bull market, BofA warned
HawkEye 360, a provider of satellite-based signals intelligence for U.S. government agencies, has gone public in a deal priced at the top of the marketed range / Photo: X / HawkEye 360
Small Caps·
HawkEye 360 IPO: Surveillance firm debuts on the NYSE
Suja Life plans to use the proceeds from the share placement for brand marketing / Photo: Suja Life
News·
Suja Life IPO: shares in the juice maker have become available. It is a competitor of Coca-Cola
SpaceX is implementing a governance structure ahead of its IPO that concentrates control in Elon Musk and significantly limits the rights of future shareholders, writes Reuters / Photo: Unsplash/SpaceX
News·
SpaceX IPO will unprecedentedly increase Musk's power at the expense of shareholder rights - Reuters
Partnering with private equity funds will give Anthropic access to hundreds of non-public corporate clients / Photo: PhotoGranary02/Shutterstock.com
News·
Anthropic and Wall Street giants prepare $1.5 billion project to sell AI to businesses
Elon Musk is pushing the idea of accelerating SpaceXs inclusion in the S&P 500 after its IPO, which is set to be the largest in history / Photo: Alessia Pierdomenico/Shutterstock.com
News·
S&P goes after SpaceX, Uzbekistan fund to offer discount: the main thing about the IPO by Ma. 3
Hemab is developing therapies for blood coagulation disorders such as Glanzmann thrombasthenia and Von Willebrand Disease, according to its filings / Photo: Hemab Therapeutics
Small Caps·
+1
·
Hemab IPO: Novo-backed blood disorder biotech debuts on the Nasdaq
Seaport Therapeutics shares become available / Photo: Seaport Therapeutics
News·
IPO of Seaport Therapeutics: shares of the antidepressant developer become available
Revolut expects it will take four months, not a year, to get a license in the U.S. / Photo: Peter_Fleming / Shutterstock.com
News·
"Already a verb but not yet a bank": can Revolut become a full-fledged lender before IPO?
Load more